State Key Laboratory of Natural Medicines and Jiang Su Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
J Med Chem. 2022 Jun 23;65(12):8065-8090. doi: 10.1021/acs.jmedchem.2c00172. Epub 2022 Jun 13.
Hematopoietic progenitor kinase 1 (HPK1), a hematopoietic cell-restricted member of the serine/threonine Ste20-related protein kinases, is a negative regulator of the T cell receptor, B cell receptor, and dendritic cells. Loss of HPK1 kinase function increases cytokine secretion and enhances T cell signaling, virus clearance, and tumor growth inhibition. Therefore, HPK1 is considered a promising target for tumor immunotherapy. Several HPK1 inhibitors have been reported to regulate T cell function. In addition, HPK1-targeting PROTACs, which can induce the degradation of HPK1, have also been developed. Here, we provide an overview of research concerning HPK1 protein structure, function, and inhibitors and propose perspectives and insights for the future development of agents targeting HPK1.
造血祖细胞激酶 1(HPK1)是丝氨酸/苏氨酸 Ste20 相关蛋白激酶家族中特有的造血细胞限制性成员,是 T 细胞受体、B 细胞受体和树突状细胞的负调节剂。HPK1 激酶功能的丧失会增加细胞因子的分泌,并增强 T 细胞信号转导、病毒清除和肿瘤生长抑制。因此,HPK1 被认为是肿瘤免疫治疗的一个有前途的靶点。已经有几种 HPK1 抑制剂被报道可以调节 T 细胞功能。此外,还开发了靶向 HPK1 的 PROTAC,它可以诱导 HPK1 的降解。在这里,我们提供了关于 HPK1 蛋白结构、功能和抑制剂的研究概述,并为未来靶向 HPK1 的药物的发展提出了展望和见解。